5 completed, 2 recruiting. 5 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Recruiting 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Recruiting 1 |
Follow Zilebesiran: new trials by email Literature Review of Zilebesiran trials Research Report on Zilebesiran
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran ALN-AGT01 RVR, Placebo, Zilebesiran - Hypertension | Phase 2 | Recruiting | Alnylam Pharmaceuticals | 93 | 2026-04-27 | 2026-10-08 |
| Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease Zilebesiran, Placebo - High Risk Cardiovascular Disease, Hypertension | Phase 3 | Recruiting | Alnylam Pharmaceuticals | 11000 | 2025-09-06 | 2026-10-15 |
| A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension Zilebesiran, Placebo - Mild to Moderate Hypertension | Phase 1 / Phase 2 | Completed | Alnylam Pharmaceuticals | 36 | 2024-06-05 | 2026-04-30 |
| Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) Zilebesiran, Placebo - High Cardiovascular Risk, Hypertension | Phase 2 | Completed | Alnylam Pharmaceuticals | 375 | 2024-02-29 | 2026-03-02 |
| Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) Indapamide, Amlodipine, Olmesartan - Hypertension | Phase 2 | Completed | Alnylam Pharmaceuticals | 663 | 2021-11-05 | 2025-11-03 |
| A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension Placebo, ALN-AGT01 - Hypertension | Phase 2 | Completed | Alnylam Pharmaceuticals | 394 | 2021-07-07 | 2025-12-23 |
| A Study to Evaluate ALN-AGT01 in Patients With Hypertension ALN-AGT01, ALN-AGT01-Matching Placebo, Irbesartan - Hypertension | Phase 1 | Completed | Alnylam Pharmaceuticals | 124 | 2019-05-01 | 2023-01-17 |
Hypertension (7) · Cardiovascular Diseases (2) · Renal Insufficiency, Chronic (1)
United Kingdom (5) · United States (5) · Canada (4) · Australia (2) · Germany (2) · Japan (2) · Poland (2) · Puerto Rico (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Chile (1) · China (1)
PMID 37467498, PMID 38363577, PMID 40434761, PMID 40556120, PMID 41388232
2019 (1), 2025 (1)